Given the globally negative results of imatinib when used in patients with COVID‐19,11 it is likely that the protective role of bosutinib, if confirmed, could therefore reside in its Lyn inhibitory activity rather than in a direct effect on SARS‐CoV‐2, an effect observed at concentrations higher than those achieved in vivo. This evidence concerns the gene LYN and COVID-19.